PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
August 20, 20250 citationsOpen Access

Figure 4 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

View Full Paper
SLSamantha I. LiangZQZoe QuandtSWSara Wienke

Key Points

  • Methylation-based ctDNA changes predict long-term benefits from immune checkpoint inhibitors in patients with various cancers, leading to targeted therapies.
  • In a subset of 75 patients, RECIST response predictably correlates with real-world progression-free survival (rwPFS) outcomes, enhancing prognostic capabilities.
  • Analysis using Kaplan-Meier plots and forest models demonstrates significant predictive value of methylation responses, improving treatment decision-making.
  • The findings suggest that combining ctDNA assessment with RECIST may enhance clinical outcomes for cancer patients undergoing immunotherapy.

Abstract

A–E, MR outcome prediction is complementary to RECIST in subset of patients with 6-month best RECIST response available (n = 75). Kaplan–Meier plots for rwPFS. A, RECIST association with rwPFS by two groups combining CR/PR/SD vs. PD. B, MR and nMR at any timepoint association with rwPFS in the RECIST subset. C, Waterfall plot of greatest percentage TF change (best MR) within 6 months by RECIST response. D, SD patients stratified by MR and nMR at any timepoint and association with rwPFS (n = 31). E, Forest plot of the CPH model with RECIST included (CR/PR/SD vs. PD) as a covariate.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Liang et al. (2025) studied this question.

synapsesocial.com/papers/68af55d8ad7bf08b1eadc77chttps://doi.org/10.1158/2767-9764.29948102
Ask AI
Helpful
Bookmark
Share
View Full Paper